IP Library Granted Patent US 9,175,353
Granted Patent B2
US 9,175,353 · App. 13/128,384 · Granted Nov 3, 2015

Compositions, kits and methods for detection of campylobacter nucleic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,175,353
App. No.
13/128,384
Granted
Nov 3, 2015
Kind
B2
Abstract

The disclosed invention is related to compositions, kits and methods comprising one or more oligomers targeting 16S rRNA target nucleic acid from Campylobacter species jejuni, coli and/or lari . Compositions include amplification oligomers, detection probe oligomers and/or target capture oligomers. Kits and methods comprise at least one of these oligomers.

Claims (30)

1. A method for specifically detecting a Campylobacter target nucleic acid in a sample comprising the steps of:

(a) contacting a sample suspected of containing at least a Campylobacter target nucleic acid with at least two amplification oligomers that stably hybridize to a C. jejuni target nucleic acid and a C. coli , a C. lari , or a C. coli and a C. lari target nucleic acid, wherein a first of said amplification oligomers comprises SEQ ID NO:26 or SEQ ID NO:32 and wherein a second of said amplification oligomers comprises a target hybridizing sequence 15 to 45 nucleotides in length and configured to target a sequence in a region of a Campylobacter 16S rRNA gene corresponding to nucleotides 170 to 226 of GenBank Accession No.: AF393202.1, gi:20378208;

(b) performing an in vitro nucleic acid amplification reaction wherein any of a C. jejuni target nucleic acid, a C. coli target nucleic acid and a C. lari target nucleic acid present in said sample is used as a template for generating an amplification product; and

(c) performing a nucleic acid detection reaction that detects said amplification product to determine whether a Campylobacter target nucleic acid was present in said sample.

2. The method of claim 1 , wherein said second of said amplification oligomers comprises a target hybridizing sequence configured to target a sequence in a region of a Campylobacter 16S rRNA gene selected from the group consisting of: a region corresponding to nucleotides 170 to 212 of GenBank Accession No.: AF393202.1, gi:20378208; a region corresponding to nucleotides 184 to 212 of GenBank Accession No.: AF393202.1, gi:20378208; and a region corresponding to nucleotides 170 to 205 of GenBank Accession No.: AF393202.1, gi:20378208; or wherein said second amplification oligomer is selected from the group consisting of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; and SEQ ID NO:14.

3. The method of claim 1 , wherein said first of said amplification oligomers comprises SEQ ID NO:26.

4. The method of claim 1 , wherein said first of said amplification oligomers comprises SEQ ID NO:32.

5. The method of claim 1 , wherein said first amplification oligomer is SEQ ID NO:26 and said second amplification oligomer is selected from the group consisting of SEQ ID NOS:1 through 14.

6. The method of claim 1 , wherein said second amplification oligomer consists essentially of SEQ ID NO:7.

7. The method of claim 1 , wherein step b. further comprises contacting said sample with a blocker oligomer.

8. The method of claim 7 , wherein said blocker oligomer consists essentially of SEQ ID NO:50.

9. The method of claim 1 , wherein said detection reaction comprises contacting said amplification product with a detection probe oligomer configured to hybridize to a portion of said amplification product.

10. The method of claim 9 , wherein said detection is real-time detection.

11. The method of claim 9 , wherein said detection oligomer is selected from the group consisting of SEQ ID NOS:63 through 68.

12. The method of claim 9 , wherein said detection oligomer consists essentially of SEQ ID NO:67.

13. The method of claim 9 , wherein said detection oligomer consists essentially of SEQ ID NO:68.

14. The method of claim 9 , wherein said second amplification oligomer is SEQ ID NO:7.

15. The method of claim 14 , wherein said detection reaction comprises contacting said amplification product with a detection probe oligomer selected from the group consisting of SEQ ID NO:67 and SEQ ID NO:68.

16. The method of claim 15 , wherein said first amplification oligomer is SEQ ID NO:26, and wherein step b. further comprises contacting said sample with a blocker consisting essentially of SEQ ID NO:50.

17. The method of claim 15 , wherein said first amplification oligomer is SEQ ID NO:32, and wherein step b. further comprises contacting said sample with a blocker consisting essentially of SEQ ID NO:50.

18. The method of claim 1 , further comprising the step of contacting said sample suspected of containing a Campylobacter target nucleic acid with a target capture oligomer.

19. The method of claim 18 , wherein said target capture oligomer is selected from the group consisting of SEQ ID NOS:58, 71 and 73.

20. The method of claim 1 , wherein said sample further contains nucleic acid from one or more bacteria closely related to C. jejuni; C. coli , or C. lari and said target nucleic acid is specifically detected in said sample.

21. The method of claim 20 , wherein said one or more bacteria is at least one of: C. Fetus , ssp. fetus, C. fetus ssp venerealis, C upsaliensis, E. coli, C. fecalis, S. enteridis, H. pylori, E. vulnaris, E. hermannii, Enterobacter cloacae, Edwardsiella hoshinae, P. miribalis, Citrobacter brakii, Pseudomonas fluorescens, Shigella flexneri, Aeromonas hydrophila, A. butzleri, C. Fetus, ssp. fetus, C. fetus ssp venerealis , and C. upsaliensis.

22. The method of claim 1 , wherein at step c said target nucleic acid is specifically amplified in the presence of a nucleic acid from one or more bacteria closely related to C. jejuni; C. coli , or C. lari.

23. The method of claim 22 , wherein said one or more bacteria is at least one of: C. Fetus , ssp. fetus, C. fetus ssp venerealis, C upsaliensis, E. coli, C. fecalis, S. enteridis, H. pylori, E. vulnaris, E. hermannii, Enterobacter cloacae, Edwardsiella hoshinae, P. miribalis, Citrobacter brakii, Pseudomonas fluorescens, Shigella flexneri, Aeromonas hydrophila, A. butzleri, C. Fetus , ssp. fetus, C. fetus ssp venerealis , and C. upsaliensis.

24. A method for specifically detecting a Campylobacter target nucleic acid in a sample comprising the steps of:

(a) contacting a sample suspected of containing at least a Campylobacter target nucleic acid with at least two amplification oligomers that stably hybridize to a C. jejuni target nucleic acid and a C. coli , a C. lari , or a C. coli and a C. lari target nucleic acid, wherein a first of said amplification oligomers is a promoter based amplification oligomer comprising a target hybridizing sequence that is SEQ ID NO:27 or SEQ ID NO:33 and further comprising a 5′ promoter sequence that is SEQ ID NO:75 and wherein a second of said amplification oligomers comprises a target hybridizing sequence 15 to 45 nucleotides in length and configured to target a sequence in a region of a Campylobacter 16S rRNA gene corresponding to nucleotides 170 to 226 of GenBank Accession No.: AF393202.1, gi:20378208;

(b) performing an in vitro nucleic acid amplification reaction wherein any of a C. jejuni target nucleic acid, a C. coli target nucleic acid and a C. lari target nucleic acid present in said sample is used as a template for generating an amplification product; and

(c) performing a nucleic acid detection reaction that detects said amplification product to determine whether a Campylobacter target nucleic acid was present in said sample.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2011
From: RESHATOFF, MICHAEL R., JR.; BUNGO, JENNIFER J.; KAPLAN, SHANNON K.; HOGAN, JAMES J.
To: GEN-PROBE INCORPORATED
Reel/Frame 026929/0819 →